Xiaojie Wu

机构：Fudan University, Fudan University Shanghai Cancer Center, Binzhou People's Hospital, Hangzhou DAC Biotech (China), Huashan Hospital, Anhui Normal University · ORCID：0000-0002-0081-6507

发表论文 84 篇 · 总被引 1241 次 · h-index 21

代表论文

• Claudin 18.2-targeting antibody–drug conjugate CMG901 in patients with advanced gastric or gastro-oesophageal junction cancer (KYM901): a multicentre, open-label, single-arm, phase 1 trial (2025 · The Lancet Oncology · 被引 61)
• A phase 1 trial of claudin 18.2-specific antibody-drug conjugate CMG901 in patients with advanced gastric/gastroesophageal junction cancer. (2023 · Journal of Clinical Oncology · 被引 22)
• First-in-human study to evaluate the safety, tolerability, and population pharmacokinetic/pharmacodynamic target attainment analysis of FL058 alone and in combination with meropenem in healthy subjects (2023 · Antimicrobial Agents and Chemotherapy · 被引 9)
• Pharmacokinetics and safety of colistin sulfate after single and multiple intravenous doses in healthy Chinese subjects (2024 · International Journal of Antimicrobial Agents · 被引 8)
• Safety, tolerability, and pharmacokinetics of a novel anti-influenza agent ZX-7101A tablets in healthy chinese participants: A first-in-human phase I clinical study (2024 · International Journal of Antimicrobial Agents · 被引 7)
• Safety and pharmacokinetics of IBI112, an IL-23 monoclonal antibody, in Chinese healthy volunteers: a first-in-human phase 1 study (2023 · Expert Opinion on Investigational Drugs · 被引 6)